Therapeutic Modulation of Gut Microbiota for Cardiovascular Disease: A Survey

www.surveyx.cn

Abstract

This survey paper explores the intricate relationship between gut microbiota and cardiovascular health, emphasizing the therapeutic potential of microbiota modulation. Cardiovascular diseases (CVDs) remain a leading cause of global mortality, with coronary artery disease (CAD) as a major contributor. Recent research highlights the gut microbiome's significant role in modulating host metabolic pathways and influencing CVD pathogenesis. Key microbial metabolites, such as trimethylamine-N-oxide (TMAO) and short-chain fatty acids (SCFAs), emerge as both biomarkers and potential therapeutic targets. The paper systematically reviews the role of gut microbiota across various stages of CAD, focusing on the potential of probiotics, prebiotics, and dietary interventions to modulate microbial communities and improve cardiovascular outcomes. Despite promising findings, the field faces challenges, including establishing causality, individual response variability, and technological limitations. The paper also discusses the potential of microbiome engineering to rectify dysbiosis and enhance metabolic pathways, offering innovative therapeutic strategies. Future research directions include mechanistic studies, personalized approaches, and technological advancements to better understand and harness the gut-heart axis. This comprehensive analysis underscores the significance of gut microbiota in cardiovascular therapeutics and highlights opportunities for future innovations in this domain.

1 Introduction

1.1 Global Impact of Cardiovascular Disease

Cardiovascular diseases (CVDs) are the leading cause of mortality globally, significantly contributing to annual death tolls. Coronary artery disease (CAD) is a primary factor in this burden, emphasizing the urgent need for effective prevention and treatment strategies [1]. The prevalence of CVDs spans all demographics, presenting a universal health challenge that necessitates a coordinated global response. Recent studies have increasingly linked alterations in gut microbiome composition to various cardiovascular conditions, including CAD, suggesting that gut microbiota could serve as a novel therapeutic target in managing these diseases [2]. Addressing the global impact of CVD requires a multifaceted approach that considers the interplay of genetic, environmental, and microbial factors in its pathogenesis.

1.2 Emerging Interest in Gut Microbiota

The rising interest in gut microbiota as a therapeutic target for cardiovascular health stems from its crucial role in modulating host metabolic pathways and influencing disease mechanisms. Research indicates that gut dysbiosis, characterized by an imbalance in gut microbiota, can significantly affect the underlying mechanisms of CVD. Dysbiosis is associated with impaired gut barrier integrity and heightened intestinal inflammation, leading to increased levels of harmful microbial metabolites, such as trimethylamine-N-oxide (TMAO) and short-chain fatty acids. These metabolites may exacerbate



Figure 1: chapter structure

CVD risk factors, including hypertension and atherosclerosis. Additionally, lifestyle factors like diet and physical inactivity can induce gut dysbiosis, further positioning gut microbiota as a potential target for CVD prevention and management [3, 4]. The exploration of gut microbial metabolites highlights their dual role as biomarkers and potential causative agents in CVD, influencing both disease prediction and therapeutic intervention.

Dietary metabolism, intrinsically linked to gut microbiota, also impacts cardiovascular outcomes, as evidenced by studies on heart failure and atherosclerosis. Modulating gut microbiota through dietary interventions, such as probiotics and prebiotics, presents a promising strategy for CVD prevention and treatment, although the efficacy of these approaches warrants further investigation. Furthermore, the role of gut-derived low-grade endotoxemia in atherothrombosis underscores the need to address the mechanisms connecting gut microbiota, inflammation, and cardiovascular outcomes [5]. Despite extensive research, a notable gap exists in human data directly linking specific gut microbes to CAD, highlighting the need for further studies to elucidate these connections [2]. The potential of microbiome engineering to alter gut microbiota composition as a novel therapeutic strategy is gaining traction, emphasizing the importance of gut microbiota in cardiovascular health. This expanding body of research not only highlights the significance of gut microbiota in CVD but also paves the way for innovative therapeutic approaches aimed at improving cardiovascular outcomes through microbiome modulation.

1.3 Purpose and Scope of the Survey

This survey provides a comprehensive analysis of the intricate relationship between gut microbiota and cardiovascular health, focusing on the therapeutic potential of probiotics and prebiotics [6]. By systematically examining the role of gut microbiota across various stages of CAD, the survey aims to establish a framework for developing diagnostic classifiers based on microbial and metabolic profiles

AI-generated, for reference only.

[1]. The review encompasses atherosclerosis and heart failure, emphasizing the influence of dietary components and the potential for therapeutic interventions targeting gut dysbiosis.

The survey also addresses critical knowledge gaps regarding how gut dysbiosis contributes to the development and progression of CVDs, underscoring the need for further research in this area [4]. It explores the role of microbial metabolites, such as TMAO, short-chain fatty acids (SCFAs), and bile acids, in CVD pathogenesis and their implications for therapeutic strategies [7]. By excluding unrelated dietary components and non-gastrointestinal factors, the survey maintains a focused analysis on the impact of gut microbiota on cardiovascular health [6]. This targeted approach not only highlights the importance of gut microbiota in CVD therapeutics but also aims to facilitate future innovations in microbiome modulation to enhance cardiovascular outcomes [8].

1.4 Structure of the Survey

The survey is systematically organized to explore the therapeutic potential of gut microbiota modulation in CVD management comprehensively. The introduction outlines the significant global burden of CVDs, which account for a considerable portion of morbidity and mortality, while highlighting the growing interest in gut microbiota as a therapeutic target. It establishes the context for the survey by detailing how gut dysbiosis may contribute to CVD pathogenesis through mechanisms such as microbial metabolite production and immune system interactions, thereby setting clear objectives for the exploration of innovative microbiome-based preventative and therapeutic strategies [9, 3, 10, 4].

The second section, *Background and Definitions*, delves into foundational concepts necessary for understanding the survey's thematic focus, including detailed definitions of CVD, gut microbiota, and microbiome engineering, along with the metabolic pathways influenced by gut microbiota and the health implications of microbial metabolites.

The third section, *Role of Gut Microbiota in Cardiovascular Health*, examines the intricate relationship between gut microbiota and cardiovascular health, emphasizing the microbiota's influence on metabolic pathways and its contribution to CVD pathogenesis. This section is further divided into subsections addressing specific aspects, such as lipid metabolism, systemic inflammation, and CVD risk factors.

The fourth section, *Therapeutic Approaches Targeting Gut Microbiota*, explores various strategies for modulating gut microbiota to enhance cardiovascular health, including probiotics, prebiotics, and dietary interventions. It also investigates the modulation of TMAO levels and its cardiovascular implications.

In *Clinical Applications and Challenges*, the fifth section evaluates current clinical applications of gut microbiota modulation in treating CVDs, addressing challenges and limitations encountered in clinical settings. This includes discussions on establishing causal relationships, individual response variability, and technological and methodological limitations.

The sixth section, *Microbiome Engineering for Cardiovascular Health*, details advancements in microbiome engineering and its potential to improve cardiovascular health by influencing metabolic pathways. It explores the development of engineered microbiomes as therapeutic targets and examines the regulatory mechanisms involved.

The survey concludes with *Future Directions and Research Opportunities*, identifying gaps in current research and proposing future research directions. This section emphasizes the need for mechanistic studies and the potential for personalized approaches and precision medicine in gut microbiota-based therapies for CVDs. Additionally, it highlights technological advancements and model development opportunities that could further research in this domain.

The *Conclusion* synthesizes the key findings of the survey, underscoring the critical role of gut microbiota modulation in the pathogenesis and treatment of CVDs. Dysbiosis, or imbalance in gut microbiota, is linked to CVD progression through mechanisms such as increased intestinal inflammation and altered microbial metabolites, influencing cardiovascular risk factors. Furthermore, the conclusion outlines the promising potential for innovative therapeutic strategies targeting gut microbiota to enhance CVD prevention and treatment, paving the way for future research in this vital area of cardiovascular health [7, 3, 9, 4, 10].The following sections are organized as shown in Figure 1.

2 Background and Definitions

2.1 Cardiovascular Disease Overview

Cardiovascular disease (CVD) encompasses a spectrum of heart and blood vessel disorders, with coronary artery disease (CAD) being the most prevalent. CAD is primarily caused by atherosclerosis, characterized by lipid accumulation and inflammatory cell infiltration, leading to plaque formation and potential myocardial infarction (MI) [2]. Atherosclerosis is a pivotal mechanism in CVD, significantly contributing to global cardiac morbidity and mortality, as MI can precipitate heart failure and is a primary cause of cardiac death worldwide.

The etiology of CVD is multifactorial, involving genetic, environmental, and microbial factors. Recent studies emphasize the gut microbiota's role in cholesterol metabolism and CVD pathogenesis, with dysbiosis linked to systemic inflammation and atherothrombosis, increasing cardiovascular risk [5]. Dietary interventions, such as probiotics and prebiotics, show promise in CVD prevention and treatment [6].

Gut microbiota and their metabolites significantly influence inflammation and atherosclerosis, impacting CVD development [7]. Biomarkers from gut microbiome and metabolomic analyses offer insights into CAD severity and guide therapeutic interventions [1]. Personalized medicine approaches, considering factors like histo-blood group glycans, may enhance disease susceptibility assessment and therapeutic responses in CVD management [11]. Understanding these interactions is crucial for developing strategies to reduce the global burden of cardiovascular diseases.

2.2 Gut Microbiota and Its Role

The human gut microbiota, a complex community of trillions of microorganisms, primarily bacteria, resides in the gastrointestinal tract, playing a vital role in host health by participating in digestion, immune modulation, and the synthesis of vitamins and bioactive compounds [1]. The composition of gut microbiota is influenced by diet, genetics, and environmental exposures, leading to significant individual variations [12].

A central function of gut microbiota is the metabolism of dietary components, profoundly affecting host lipid metabolism and cardiovascular health. Gut microbiota modulates lipid profiles, with probiotics and prebiotics showing potential benefits in lipid metabolism [13]. Microbial metabolites, including trimethylamine (TMA), converted to trimethylamine-N-oxide (TMAO) in the liver, and short-chain fatty acids (SCFAs), mediate the relationship between diet, gut microbiota, and cardiovascular outcomes, influencing inflammatory processes and atherosclerosis [5].

Maintaining intestinal barrier integrity is crucial; its disruption, known as 'leaky gut', can lead to systemic inflammation, associated with metabolic and autoimmune diseases [14]. In chronic kidney disease (CKD) patients, dysbiosis correlates with elevated uremic toxins and inflammation, adversely affecting health outcomes [15].

Dietary components, such as proteins, fats, carbohydrates, and polyphenols, significantly influence gut microbiota composition and function, suggesting that dietary interventions can modulate microbial communities and improve health outcomes [16]. Recognizing gut microbiota as a pivotal factor in the diet-health axis opens avenues for therapeutic strategies aimed at enhancing health through microbiome modulation [17]. Understanding gut microbiota-host interactions is essential for developing interventions to mitigate health risks and enhance well-being.

2.3 Microbiome Engineering

Microbiome engineering is an emerging field focused on modifying gut microbiota to achieve specific health outcomes. This approach employs advanced biotechnological tools to alter microbial communities, aiming to rectify dysbiosis and enhance health benefits, particularly in cardiovascular diseases (CVDs) [2].

A key area of microbiome engineering is the interplay between gut microbiota and host lipid metabolism. Dysbiosis, characterized by microbial imbalance, has been linked to hyperlipidemia and metabolic disorders. Research categorizes these interactions, establishing a framework to understand the regulatory mechanisms by which gut microbiota influences lipid metabolism, highlighting the potential for engineered interventions to restore balance and improve lipid profiles [13].

Innovative models, like the two-layer interaction model, simulate gut bacteriome dynamics through molecular communications, providing insights into how engineered modifications affect microbial behavior and host health [12]. This approach emphasizes microbiome engineering's potential to address complex health issues by targeting specific microbial interactions and pathways.

Dietary interventions targeting gut microbiota offer promising strategies for mitigating heart failure progression. By engineering the microbiome, it is feasible to influence the production of key microbial metabolites, such as SCFAs and TMAO, crucial for cardiovascular health [18]. These interventions could alter CVD trajectories by modulating gut microbiota's metabolic outputs.

Beyond metabolic regulation, microbiome engineering can address disease associations through glycan biosynthesis pathway manipulation. Organizing research into glycan structural variation and functional relevance may lead to new therapeutic applications exploiting gut microbiota's role in disease pathogenesis and treatment [11]. This highlights microbiome engineering's multifaceted nature and its potential to revolutionize health interventions through targeted microbial modifications.

2.4 Metabolic Pathways and Microbial Metabolites

Gut microbiota significantly influences host metabolic pathways, with microbial metabolites playing crucial roles in health and disease. Trimethylamine-N-oxide (TMAO), a key metabolite derived from dietary sources like choline and carnitine, is increasingly recognized for its involvement in atherosclerosis and various cardiovascular diseases (CVDs). Elevated TMAO levels correlate with increased inflammation, impaired cholesterol metabolism, and heightened platelet aggregation, all contributing to atherosclerosis progression. Consequently, TMAO has emerged as a significant biomarker and therapeutic target for strategies aimed at mitigating cardiovascular disease progression and enhancing patient outcomes [19, 20].

Short-chain fatty acids (SCFAs), including butyrate, propionate, and acetate, are produced through dietary fiber fermentation by gut bacteria. These metabolites are essential for maintaining lipid and glucose homeostasis, modulating immune responses, and preserving intestinal barrier integrity, thereby positively influencing cardiovascular health. SCFAs also play a role in reducing systemic inflammation, a critical factor in cardiovascular disease development [21].

Bile acids, synthesized in the liver and modified by gut microbiota, are vital for lipid metabolism and energy homeostasis. The interaction between bile acids and gut microbiota affects enterohepatic circulation, influencing cholesterol metabolism and cardiovascular health [4]. Additionally, microbial metabolism of branched-chain amino acids and polyphenols contributes to metabolic regulation and disease prevention, illustrating the diverse roles of microbial metabolites in health [9].

The intricate relationship between diet, gut microbiota, and metabolic pathways underscores the significance of dietary fiber for gut health and microbiota's influence on metabolic processes [8]. Personalized nutrition approaches, tailored to individual microbiome profiles, are increasingly recognized for their potential to optimize health outcomes [16]. The DiMB-RE dataset, focusing on diet-microbiome interactions, provides a comprehensive framework for exploring these relationships, highlighting the potential for dietary and probiotic interventions to modulate gut microbiota composition and metabolic outputs [17]. Such interventions offer promising avenues for therapeutic strategies aimed at improving cardiovascular outcomes [3].

In recent years, the role of gut microbiota in cardiovascular health has garnered significant attention within the scientific community. Understanding the intricate relationships between gut microbiota and cardiovascular disease is crucial for developing effective therapeutic strategies. As illustrated in Figure 2, this figure delineates the hierarchical structure of these relationships, categorizing the connections between gut microbiota and various aspects of cardiovascular disease pathogenesis. It highlights key areas such as lipid metabolism, systemic inflammation, and cardiovascular disease (CVD) risk factors. Each of these categories is further subdivided into specific mechanisms, impacts, and potential therapeutic interventions, thereby providing a comprehensive overview of the multifaceted interactions at play. This structured representation not only enhances our understanding of the underlying processes but also underscores the importance of gut microbiota as a target for future cardiovascular health interventions.



Figure 2: This figure illustrates the hierarchical structure of the role of gut microbiota in cardiovascular health, categorizing the connections between gut microbiota and cardiovascular disease pathogenesis, lipid metabolism, systemic inflammation, and CVD risk factors. Each category is further divided into specific mechanisms, impacts, and potential therapeutic interventions.

3 Role of Gut Microbiota in Cardiovascular Health

3.1 Gut Microbiota and Cardiovascular Disease Pathogenesis

The pathogenesis of cardiovascular disease (CVD) is intricately linked to gut microbiota composition and function. Patients with advanced coronary artery disease (CAD) exhibit reduced alpha diversity and distinct microbial taxa compared to healthy controls, indicating a specific gut microbiome profile associated with CAD severity [2, 1]. Gut microbiota influences cardiovascular health through the production of trimethylamine-N-oxide (TMAO), a metabolite derived from dietary choline and carnitine, which correlates with increased cardiovascular risk [20]. While the precise mechanisms by which TMAO contributes to atherosclerosis are still being explored, the established links between gut microbiota and CAD highlight potential therapeutic targets and dietary interventions for improving cardiovascular health [10, 18].

Moreover, factors such as histo-blood group glycans modulate the gut microbiota's role in immune recognition and disease susceptibility, suggesting avenues for personalized therapeutic strategies [11]. The hypothesis that gut microbial translocation induces inflammation post-myocardial infarction (MI) underscores the significance of gut microbiota dynamics in post-MI inflammation and thrombosis [22]. Research encompasses gut microbiota composition, permeability, and the role of lipopolysaccharides (LPS) in inflammation, with clinical studies linking endotoxemia to cardiovascular events [5].

As illustrated in Figure 3, the hierarchical categorization of gut microbiota's role in CVD pathogenesis highlights microbial composition, metabolite influence, and immune/inflammatory responses as key areas of focus. A two-layer interaction model simulating human gut bacteriome dynamics reveals crucial relationships between bacterial populations and metabolite production, informing potential therapeutic interventions [12]. These findings collectively emphasize the critical role of gut microbiota in CVD pathogenesis and the promise of microbiome-targeted therapies for improving cardiovascular outcomes.

3.2 Gut Microbiota and Lipid Metabolism

Gut microbiota plays a pivotal role in modulating lipid metabolism, significantly impacting cardiovascular health. Dysbiosis is associated with hyperlipidemia, a major risk factor for atherosclerosis [13]. The metabolite TMAO, produced by gut microbiota, influences lipid metabolism by affecting cholesterol levels and transport, thereby contributing to atherosclerosis [20]. Additionally, gut microbiota generates short-chain fatty acids (SCFAs), such as acetate, propionate, and butyrate, through dietary fiber fermentation, which are crucial for regulating lipid metabolism and energy balance [1, 13, 4]. These SCFAs modulate lipid synthesis and breakdown, influencing cardiovascular health.

The interplay between dietary patterns, gut microbiota, and lipid metabolism suggests that targeted dietary interventions, including probiotics and prebiotics, can effectively alter gut microbiota composition and improve lipid profiles. Research indicates that specific dietary components can rapidly



Figure 3: This figure illustrates the hierarchical categorization of gut microbiota's role in cardiovascular disease (CVD) pathogenesis, highlighting microbial composition, metabolite influence, and immune/inflammatory responses as key areas of focus.

shift gut microbial populations, influencing metabolic and immune responses, offering therapeutic benefits for managing hyperlipidemia and related cardiovascular conditions [13, 16, 4]. Understanding these complex interactions is essential for developing novel therapeutic approaches to optimize lipid metabolism and enhance cardiovascular health.

3.3 Gut Microbiota and Systemic Inflammation

Gut microbiota is crucial in modulating systemic inflammation, a key factor in CVD pathogenesis. Dysbiosis can lead to increased intestinal permeability, or 'leaky gut', allowing microbial products like lipopolysaccharides (LPS) to enter systemic circulation, triggering inflammation associated with atherosclerosis [14]. LPS from Gram-negative bacteria activates immune cells and releases pro-inflammatory cytokines, contributing to endothelial dysfunction and atherosclerotic plaque development. LPS translocation, facilitated by gut dysbiosis, leads to low-grade endotoxemia, linked to increased atherosclerotic burden and cardiovascular events [3, 4, 22, 5, 21]. This systemic inflammatory state exacerbates atherosclerosis and heightens the risk of cardiovascular incidents. Conversely, microbial metabolites like SCFAs may mitigate inflammation, showcasing the complex interplay between gut microbiota and immune regulation.

Understanding how gut microbiota influences systemic inflammation is vital for developing therapies aimed at restoring microbial balance and reducing cardiovascular risk. Interventions such as probiotics, prebiotics, and dietary changes hold promise for improving cardiovascular health by targeting inflammatory pathways influenced by gut microbiota, addressing mechanisms of CVD progression, and introducing innovative strategies for prevention and management [7, 4].

3.4 Gut Microbiota and CVD Risk Factors

Gut microbiota significantly impacts various CVD risk factors by modulating metabolic and inflammatory pathways that contribute to disease progression. TMAO, a microbial metabolite, serves as a biomarker for stroke and CVD, promoting atherosclerosis and inflammation, and highlighting its potential as a target for therapeutic strategies [19]. The DiMB-RE dataset illustrates the complex interplay between diet, metabolism, and gut microbiota, providing insights into how dietary components influence microbial communities and cardiovascular risk factors [17].

Modulating gut microbiota through probiotics and prebiotics presents promising avenues for reducing CVD risk by improving lipid profiles, enhancing glucose metabolism, and decreasing systemic inflammation. A comprehensive understanding of the interactions between gut microbiota and CVD risk factors is crucial for developing targeted therapies to prevent and manage CVD, particularly by addressing gut dysbiosis linked to obesity, dietary habits, and sedentary lifestyles. Restoring gut health and microbial diversity could mitigate inflammation, improve gut barrier integrity, and regulate metabolites like TMAO and SCFAs implicated in CVD pathogenesis, making the gut microbiome a promising target for innovative CVD prevention and treatment strategies [7, 3, 6, 4, 10].

4 Therapeutic Approaches Targeting Gut Microbiota

4.1 Probiotics and Prebiotics

Probiotics and prebiotics are pivotal in modulating gut microbiota to enhance cardiovascular health. Probiotics, live microorganisms administered in sufficient quantities, have shown potential in improving lipid profiles and reducing systemic inflammation, which are critical factors in managing cardiovascular disease (CVD) [8]. Prebiotics, non-digestible food components that selectively promote beneficial gut bacteria, improve the gut environment and support the proliferation of health-promoting microbial communities [15].

The effectiveness of these microbiota-targeted interventions varies, necessitating personalized approaches for managing hyperlipidemia and other cardiovascular risk factors [13]. Individual responses differ due to variations in baseline gut microbiota composition, genetic predispositions, and dietary habits, requiring tailored therapeutic strategies for optimal outcomes.

As illustrated in Figure 4, the hierarchical relationship between probiotics and prebiotics in cardiovascular health is depicted, highlighting their respective roles and benefits, as well as the critical need for personalized interventions. Innovative methodologies, such as graph-based models integrated with molecular communications, provide insights into complex interactions within the gut bacteriome, aiding in identifying specific microbial targets for intervention [12]. Furthermore, multi-omic approaches offer promising avenues for developing novel diagnostic tools and therapeutic targets for coronary artery disease (CAD) [1]. Leveraging these advanced techniques will elucidate the mechanisms through which probiotics and prebiotics exert their beneficial effects, paving the way for more effective and personalized interventions in CVD prevention and management.



Figure 4: This figure illustrates the hierarchical relationship between probiotics and prebiotics in cardiovascular health, highlighting their roles, benefits, and the need for personalized interventions.

4.2 Dietary Interventions

Dietary interventions significantly influence gut microbiota and have profound implications for cardiovascular health. The gut microbiome responds dynamically to dietary changes, with specific strategies enhancing microbial communities and improving metabolic health and immune function [16]. Increasing dietary fibers, polyphenols, and other bioactive compounds promotes the growth of beneficial bacteria and the production of health-promoting metabolites.

High-fiber diets enhance the production of short-chain fatty acids (SCFAs)—such as butyrate, propionate, and acetate—by gut microbiota, which are vital for regulating lipid metabolism, improving glucose homeostasis, and mitigating systemic inflammation. SCFAs, produced through the fermentation of dietary fibers, contribute to gut barrier integrity and lower CVD risk by modulating inflammatory pathways and metabolic processes [18, 6, 14, 4]. Polyphenol-rich diets, including foods like berries, nuts, and green tea, have been linked to favorable shifts in gut microbiota composition, reducing inflammation and oxidative stress, thereby supporting cardiovascular health.

The impact of dietary interventions is further influenced by individual factors, such as genetics and baseline microbiota composition, highlighting the necessity for personalized nutrition approaches that optimize health outcomes and mitigate cardiovascular risk. Ongoing research continues to reveal the intricate relationships among dietary choices, gut microbiota composition, and host metabolic

AI-generated, for reference only.

processes, positioning dietary interventions as a promising strategy for enhancing cardiovascular health through targeted microbiome modulation. Evidence indicates that dietary patterns can significantly influence gut microbial populations, which produce metabolites like trimethylamine-N-oxide and SCFAs linked to cardiovascular disease risk [16, 7, 18, 4, 10].

4.3 TMAO Modulation

Modulating trimethylamine-N-oxide (TMAO) levels through gut microbiota interventions has emerged as a promising strategy for managing CVD. TMAO, a metabolite resulting from microbial metabolism of dietary choline and carnitine, serves as a critical biomarker for cardiovascular risk, with implications for clinical prognostic stratification and therapeutic targeting [20]. Elevated TMAO levels correlate with increased atherosclerosis and cardiovascular events, necessitating effective strategies to mitigate its adverse effects [19].

Current research highlights the potential of dietary and pharmacological interventions to modulate TMAO levels, emphasizing the impact of dietary components on gut microbiota composition and function. Dietary strategies, such as reducing red meat and egg consumption—rich in choline and carnitine—could lower TMAO production. Additionally, probiotics and other microbiota-targeted therapies show promise in reducing TMAO levels and, consequently, cardiovascular risk [21].

Future research should elucidate the mechanisms by which TMAO contributes to CVD pathogenesis and assess the efficacy of various interventions in modulating its levels. Understanding these mechanisms is crucial for developing targeted therapies that effectively reduce TMAO levels and enhance cardiovascular outcomes. By integrating dietary, probiotic, and pharmacological approaches, comprehensive strategies for TMAO modulation may be devised, thereby improving cardiovascular health and reducing disease burden.

5 Clinical Applications and Challenges

5.1 Clinical Applications and Challenges

Benchmark	Size	Domain	Task Format	Metric
CAD-Gut-Microbiome[2]	106	Cardiovascular Medicine	Microbiome Composition Analysis	Alpha Diversity, Differential Abundance
DiMB-RE[17]	14,450	Nutrition	Named Entity Recognition And Relation Extraction	F1-score
CAD-GM[1]	201	Cardiovascular Disease	Disease Classification	AUC, Gensini score

Table 1: The table presents a selection of benchmarks utilized in the study of cardiovascular disease (CVD) and related fields, highlighting their respective sizes, domains, task formats, and evaluation metrics. It includes datasets from cardiovascular medicine and nutrition, reflecting diverse analytical approaches such as microbiome composition analysis and disease classification.

The modulation of gut microbiota presents promising therapeutic avenues for cardiovascular disease (CVD) management, yet it is accompanied by significant challenges. While research has illuminated the microbiota's role in CVD, identifying novel therapeutic targets [21], the complexity of gut microbiota interactions and the challenge of establishing causality between dysbiosis and CVD require comprehensive human studies [4]. Inconsistencies in methodologies, particularly in measuring endotoxaemia, result in variable outcomes, limiting definitive conclusions [5]. This is exacerbated by a lack of consensus on methodologies, complicating causal link establishment between microbiota composition and cardiovascular outcomes [23].

Demographic factors such as age, sex, and ethnicity further complicate the microbiota's influence on cardiovascular health [8]. Individual variability in response to dietary and microbiota-targeted interventions highlights the need for personalized approaches [15], pointing to the limitations of current dietary recommendations that often lack robust clinical evidence [16]. Despite these challenges, innovative strategies such as targeting histo-blood group glycans and employing graph-based models with molecular communications offer promising pathways for disease prevention and treatment [11]. Dietary interventions have shown potential in improving gut microbiota and reducing uremic toxins, enhancing patient outcomes [15]. Insights into the gut-heart connection, particularly regarding myocardial infarction, suggest new therapeutic strategies targeting gut health to improve cardiovascular outcomes [22].

Significant challenges remain in establishing causality, standardizing methodologies, and translating research findings into clinical interventions. To leverage the therapeutic potential of microbiota-based interventions, it is essential to address the multifaceted challenges related to understanding complex causal relationships between gut microbiota and CVD, as well as the influence of dietary, demographic, and lifestyle factors on gut health and disease progression [9, 3, 10, 4]. Table 1 provides a detailed overview of the benchmarks employed to address the challenges in cardiovascular disease research, particularly in understanding the role of gut microbiota and the development of targeted interventions.



(a) Chao-1 in CAD Patients vs. Controls[2]



(b) Cholesterol, gut microbiota, and CAD[10]

Entity Type	Count	Percentage (%)
Chemical	1,119	7.7
DietPattern	851	5.9
Disease	604	4.2
DiversityMetric	231	1.6
Enzyme	239	1.7
Food	1,047	7.2
Gene	173	1.2
Measurement	814	5.6
Metabolite	1,181	8.2
Microorganism	1,938	13.4
Nutrient	2,045	14.2
Physiology	1,716	11.9
Biospecimen	307	2.1
Methodology	950	6.6
Population	1,235	8.5
TOTAL	14,450	100.0

(c) Entity Type Distribution in a Table[17]

Figure 5: Examples of Clinical Applications and Challenges

As illustrated in Figure 5, the examples on "Clinical Applications and Challenges" provide a comprehensive exploration of various aspects of cardiovascular disease (CAD) through visual representations. The figure "Chao-1 in CAD Patients vs. Controls" highlights differences in gene expression levels between CAD patients and controls. The diagram on "Cholesterol, gut microbiota, and CAD" elucidates the relationship between cholesterol levels, gut microbiota, and CAD development. Lastly, "Entity Type Distribution in a Table" offers a quantitative analysis of entity prevalence and distribution, crucial for understanding data patterns in clinical research. These examples underscore the multifaceted challenges and applications in CAD management, emphasizing the integration of genetic, biochemical, and data-driven approaches [2, 10, 17].

5.2 Challenges in Establishing Causal Relationships

Establishing causal links between gut microbiota and cardiovascular outcomes is challenging due to the complex interplay of dietary, genetic, and microbial factors. The role of trimethylamine-N-oxide (TMAO) in CVD exemplifies these difficulties, as conflicting evidence and individual response variability complicate its impact on cardiovascular health [20]. Elevated TMAO levels are linked to increased cardiovascular risk, but the mechanisms remain incompletely understood, necessitating further research.

The complexity of gut microbiota interactions with host metabolism further complicates causality efforts. Many studies are associative, highlighting correlations between microbial processes and heart failure without providing definitive causal links [18]. This is compounded by intricate interactions between diet, microbiota, and host metabolism, obscuring direct effects of specific microbial metabolites on CVD outcomes [7].

Individual variability in gut microbiota composition and function poses a challenge in establishing consistent causal relationships. Health outcomes are influenced by genetic predispositions, lifestyle choices, and environmental factors, alongside the gut microbiome shaped by dietary habits. Personalized approaches are necessary in research and therapeutic interventions, considering how dietary components can shift microbial composition affecting immune and metabolic functions, influencing chronic disease risk [17, 16, 4]. Comprehensive, longitudinal studies integrating multi-omic data are required to understand dynamic interactions between gut microbiota and cardiovascular health.

5.3 Variability in Individual Responses

Variability in individual responses to gut microbiota interventions poses a significant challenge in developing effective CVD therapeutic strategies. This variability is influenced by genetic predispositions, baseline gut microbiota composition, dietary habits, and environmental exposures, collectively shaping host-microbiome interactions and impacting treatment outcomes. Heterogeneity in gut microbiota among individuals leads to differential metabolic responses to dietary interventions and probiotics, complicating therapeutic efficacy prediction and necessitating personalized approaches [8].

Recent studies emphasize considering individual microbiome profiles in designing interventions for cardiovascular health benefits [17]. Multi-omic data integration, including genomics, metabolomics, and microbiomics, provides a comprehensive framework for understanding complex interactions between diet, gut microbiota, and host metabolism, facilitating tailored therapeutic strategies [12].

The variability in individual responses underscores the need for robust clinical trials accounting for demographic and genetic diversity, as well as lifestyle and dietary pattern variations [4]. Such trials are essential for identifying biomarkers to predict individual responses to microbiota-targeted therapies and optimizing treatment regimens for enhanced cardiovascular outcomes [1].

Incorporating personalized nutrition approaches aligning with individual microbiome characteristics holds promise for improving the efficacy of gut microbiota interventions in CVD management. Customizing dietary recommendations and probiotic formulations to individual microbiome profiles can enhance therapeutic intervention effectiveness for cardiovascular health. This personalized approach may lead to more reliable outcomes, advancing precision medicine. Recent studies highlight gut microbiota's significant role in cardiovascular disease, indicating tailored strategies could mitigate risk factors and improve cardiovascular health through targeted microbiome modulation [6, 10, 4].

5.4 Technological and Methodological Limitations

The study of gut microbiota's role in cardiovascular health faces technological and methodological challenges that impede research and clinical application advancement. The gut microbiome's complexity and diversity, comprising numerous microbial species with dynamic interactions, necessitate advanced sequencing technologies and bioinformatics tools for accurate microbial community characterization and functional capability assessment [4].

Current sequencing technologies, while powerful, have limitations in resolving the microbiome's full complexity, particularly in identifying low-abundance species and capturing microbiota's functional potential. Multi-omic approaches, including metagenomics, metatranscriptomics, metabolomics, and proteomics, are essential for comprehensively understanding the microbiome's role in cardiovascular health [17]. However, high costs and technical expertise requirements pose significant barriers to their widespread adoption in research and clinical settings.

Standardization of protocols for sample collection, processing, and analysis is critical for ensuring reproducibility and comparability across studies [5]. Variability in protocols can lead to inconsistent results, hindering definitive conclusions regarding causal relationships between gut microbiota and cardiovascular outcomes. Additionally, lack of standardized data analysis pipelines and complexity in interpreting multi-omic data further complicate gut microbiota studies in cardiovascular health [12].

Translating microbiome research into clinical practice is hindered by the need for robust clinical trials validating microbiota-targeted intervention efficacy. Designing and implementing such trials is challenged by individual microbiome variability and cardiovascular diseases' multifactorial nature, requiring personalized therapy approaches [1]. Addressing these technological and methodological limitations is crucial for advancing understanding of the gut microbiome's role in cardiovascular health and developing effective microbiota-based therapies.

6 Microbiome Engineering for Cardiovascular Health

The manipulation of the microbiome is emerging as a promising therapeutic strategy in cardiovascular health, addressing the complexities of cardiovascular disease (CVD) by rectifying dysbiosis and enhancing metabolic pathways to improve health outcomes.

6.1 Engineered Microbiomes as Therapeutic Targets

Engineered microbiomes represent an innovative approach to managing CVD by utilizing biotechnological tools to modify gut microbiota, aiming to rectify dysbiosis and enhance health outcomes. These microbiomes are designed to influence metabolic pathways, modulating key microbial metabolites involved in CVD pathogenesis [2]. Manipulating gut microbiota can regulate lipid metabolism, as dysbiosis is linked to hyperlipidemia and metabolic disorders, significant risk factors for atherosclerosis. Engineering microbiomes to restore microbial balance may improve lipid profiles and reduce cardiovascular risk by targeting specific bacterial populations involved in lipid synthesis and breakdown [13].

Engineered microbiomes can also modulate metabolites such as trimethylamine-N-oxide (TMAO) and short-chain fatty acids (SCFAs). TMAO, derived from dietary choline and carnitine, is associated with increased cardiovascular risk, and its modulation through microbiome engineering could reduce disease burden [20]. Enhancing SCFA production may improve glucose homeostasis and reduce systemic inflammation, supporting cardiovascular health [9]. Models like the two-layer interaction model provide insights into the dynamics of the human gut bacteriome, facilitating the identification of specific microbial targets for intervention [12].

Additionally, microbiomes can address disease associations by manipulating glycan biosynthesis pathways. Research into glycan structural variation and functional relevance can lead to new therapeutic applications, exploiting the gut microbiota's role in disease pathogenesis and treatment [11]. This multifaceted approach highlights microbiome engineering's potential to revolutionize health interventions through targeted microbial modifications.

The investigation of engineered microbiomes as therapeutic targets for CVD underscores the importance of personalized medicine, emphasizing the role of gut microbiota in CVD development and progression. Understanding interactions between gut microbiota, microbial metabolites, and the immune system may lead to innovative microbiome-based interventions that improve patient outcomes, considering factors such as diet, age, and ethnicity influencing gut health [10, 4]. Harnessing microbiome engineering may facilitate tailored interventions addressing microbial contributions to cardiovascular disease, paving the way for innovative therapeutic strategies in cardiovascular health management.

6.2 Regulatory Mechanisms and Therapeutic Potential

Regulatory mechanisms in microbiome engineering are crucial for harnessing its therapeutic potential in cardiovascular health. These mechanisms involve strategically modifying gut microbial communities to influence metabolic pathways and enhance beneficial metabolite production, such as SCFAs and TMAO, which regulate cardiovascular health and mitigate CVD risk [7, 9, 4, 10]. The interplay between gut microbiota and host metabolism is central to this process, with engineered microbiomes offering the potential to rectify dysbiosis, improve lipid profiles, reduce systemic inflammation, and enhance glucose homeostasis.

A key regulatory mechanism in microbiome engineering is the targeted manipulation of specific bacterial populations and their metabolic outputs. This involves using biotechnological tools to enhance SCFA production while reducing TMAO levels, both critical for cardiovascular health. SCFAs exert anti-inflammatory effects and improve lipid metabolism, lowering cardiovascular risk [9]. Conversely, TMAO, linked to atherosclerosis, can be modulated through dietary interventions and engineered microbiomes to mitigate its adverse effects on cardiovascular health [20].

The therapeutic potential of microbiome engineering extends to developing personalized interventions tailored to individual microbiome profiles. By integrating multi-omic data, researchers can identify specific microbial targets and pathways for intervention, facilitating the design of customized therapies addressing unique metabolic and inflammatory pathways in CVD [12]. This underscores the importance of personalized medicine in optimizing the therapeutic efficacy of microbiome-based interventions.

Exploring glycan biosynthesis pathways offers additional therapeutic avenues in microbiome engineering. Manipulating glycan structures and their interactions with gut microbiota can influence disease pathogenesis, leading to novel therapeutic applications [11]. This highlights the multifaceted nature of microbiome engineering and its potential to revolutionize cardiovascular health interventions.

The regulatory mechanisms in microbiome engineering and their therapeutic potential hold significant promise for advancing cardiovascular health. By harnessing the interactions between diet, gut microbiota, and host metabolism, researchers can devise groundbreaking therapeutic strategies targeting microbial factors contributing to CVD. This approach aims to mitigate CVD risk factors by focusing on microbial metabolites such as TMAO and SCFAs, implicated in disease progression. Establishing causal links between gut dysbiosis and cardiovascular pathogenesis may enhance patient outcomes and further the development of precision medicine tailored to individual microbiome profiles and demographic factors [7, 6, 4, 22, 10].

7 Future Directions and Research Opportunities

7.1 Mechanistic Studies and Causality

Future research should focus on elucidating the mechanistic pathways and causal relationships between gut microbiota and cardiovascular health to refine therapeutic strategies. A critical area is the role of trimethylamine-N-oxide (TMAO) in cardiovascular disease (CVD), necessitating interventions like dietary modifications and microbiota manipulation to mitigate cardiovascular risk [20]. Large-scale studies are essential for validating biomarkers and exploring the mechanistic pathways of gut metabolites, assessing the impacts of dietary interventions on microbiota composition and metabolite production [9]. Longitudinal studies will be crucial for understanding the effects of dietary and microbial interventions on gut health and cardiovascular outcomes, facilitating personalized therapy approaches based on individual microbiome profiles [4]. Standardizing methodologies for endotoxaemia measurement and investigating the effects of dietary interventions, probiotics, and prebiotics on gut health will be vital [5].

Examining interactions between gut microbiota, dietary components, and heart failure through mechanistic studies is necessary to clarify these complex relationships [18]. Longitudinal studies will also enhance our understanding of microbiota dynamics and their implications for atherosclerosis, providing insights into potential therapeutic interventions [21]. Emphasizing individualized dietary interventions based on gut microbiota profiles and exploring the synergistic effects of combined dietary components is crucial [15]. Additionally, long-term dietary studies and research into the specific mechanisms by which diet influences microbiota are essential to fill existing knowledge gaps [16].

Identifying specific bacterial strains for therapeutic targeting and examining the effects of diet and probiotics on gut health are important areas for further exploration [14]. Research should aim to elucidate the mechanisms of microbial metabolite action, explore targeted therapies, and investigate the role of diet in shaping the microbiome and its metabolic outputs [7]. These efforts, combined with large-scale clinical trials, will enhance our understanding of dynamic changes in gut microbiota composition during disease progression and inform the development of effective microbiota-targeted therapies.

7.2 Personalized Approaches and Precision Medicine

The potential for personalized approaches and precision medicine in gut microbiota-based therapies for CVD is increasingly recognized as a promising avenue for optimizing therapeutic outcomes. Future research should prioritize developing personalized nutrition strategies tailored to individual microbiome profiles, enhancing the efficacy of dietary interventions and improving cardiovascular health. These strategies focus on identifying specific microbial metabolites, such as TMAO and short-chain fatty acids, that significantly influence CVD pathogenesis. Understanding the interactions between these metabolites and host physiological processes will facilitate targeted interventions to mitigate CVD risk and improve patient outcomes [7, 9, 4, 1, 10].

Fecal microbiota transplantation (FMT) as a therapeutic strategy underscores the potential of microbiome modulation in precision medicine. FMT involves transferring gut microbiota from healthy donors to patients to restore microbial balance and improve health outcomes, particularly in dysbiosis-associated cardiovascular diseases, where conventional therapies may be less effective [3]. Further investigation into the long-term effects of dietary interventions on gut microbiota composition and cardiovascular health is warranted. Understanding the mechanisms by which gut microbiota influence health and disease is essential for developing effective precision medicine strategies [8]. By integrating multi-omic data and advanced analytical techniques, researchers can identify specific microbial targets and pathways for intervention, facilitating the design of personalized therapies that address the unique metabolic and inflammatory pathways involved in CVD.

Integrating personalized approaches and precision medicine in gut microbiota-based therapies holds significant promise for advancing cardiovascular health. Customizing therapeutic interventions based on individual gut microbiome characteristics may lead to more reliable and beneficial outcomes in cardiovascular disease management. This approach can enhance precision medicine by leveraging the intricate relationships between gut microbiota, metabolic processes, and immune responses, which are critical in developing and progressing conditions like coronary artery disease. Understanding these relationships can lead to innovative microbiome-based treatments and preventive strategies tailored to individual patient profiles, ultimately addressing the complex interplay of dietary, demographic, and microbial factors influencing cardiovascular health [7, 4, 1, 2, 10].

7.3 Technological Advancements and Model Development

Technological advancements and sophisticated model development are crucial for enhancing research into the intricate relationships between gut microbiota and cardiovascular health. These developments enable a deeper understanding of how gut dysbiosis influences CVD risk factors through mechanisms involving microbial metabolites and immune system interactions, paving the way for innovative microbiome-based therapeutic strategies aimed at preventing and treating CVD, a leading cause of global morbidity and mortality [3, 10, 4]. Cutting-edge sequencing technologies and bioinformatics tools have revolutionized our ability to characterize the gut microbiome's complexity, providing insights into its composition and functional capabilities. Integrating multi-omic approaches, such as metagenomics, metatranscriptomics, metabolomics, and proteomics, facilitates a comprehensive understanding of the microbiome's role in cardiovascular health by capturing the dynamic interactions between microbial communities and host metabolic pathways.

Innovative computational models, such as the two-layer interaction model, simulate the dynamics of the human gut bacteriome, offering valuable insights into interactions within microbial communities and their impact on host health [12]. These models help identify potential microbial targets and pathways for therapeutic intervention, enhancing our understanding of how gut microbiota can be modulated to improve cardiovascular outcomes. Furthermore, graph-based models with molecular communications provide a novel framework for exploring complex interactions within the gut microbiota, facilitating the identification of specific microbial targets and pathways for intervention [12]. This approach enhances our understanding of how probiotics and prebiotics can be effectively utilized to modulate gut microbiota and improve cardiovascular health.

The integration of artificial intelligence and machine learning techniques in microbiome research is revolutionizing the analysis of extensive datasets, enabling researchers to uncover intricate patterns and correlations that traditional analytical methods may overlook. This advancement is particularly significant given the vast knowledge regarding diet-microbiome interactions, exemplified by the development of DiMB-RE, a comprehensive annotated corpus for mining biomedical literature for diet-microbiome associations. By leveraging state-of-the-art natural language processing models, this research enables the extraction of meaningful relationships and entities from scientific publications, thereby advancing our understanding of the gut microbiota's role in human health and disease [17, 8, 10, 9]. These technologies hold the potential to accelerate the discovery of novel biomarkers and therapeutic targets, paving the way for precision medicine approaches in cardiovascular disease management.

Technological advancements and model development are integral to advancing our understanding of the gut microbiome's role in cardiovascular health. By harnessing recent advancements, researchers can create more targeted and personalized interventions that address the underlying mechanisms of gut dysbiosis. This approach not only has the potential to improve patient outcomes by mitigating cardiovascular disease risk factors but also contributes to the broader advancement of cardiovascular health research through the development of innovative microbiome-based therapies [6, 10, 4].

8 Conclusion

The survey underscores the significant influence of gut microbiota on cardiovascular disease (CVD) pathogenesis, particularly highlighting the role of microbial metabolites in conditions such as atherosclerosis. This relationship suggests that targeting gut microbiota could be a promising strategy for CVD prevention and treatment. The interaction between gut microbiota and host metabolic pathways is crucial, as it affects CVD risk, pointing to the potential of interventions that modify these microbial processes. Approaches such as dietary changes and the use of probiotics and prebiotics are promising for improving cardiovascular health. Nevertheless, further investigation is needed to elucidate the mechanisms involved and optimize these interventions for clinical application. The advancement of microbiome engineering and precision medicine holds promise for enhancing CVD therapeutics, offering the prospect of more effective and individualized treatment strategies.

AI-generated, for reference only.

References

[1] Honghong Liu, Xi Chen, Xiaomin Hu, Haitao Niu, Ran Tian, Hui Wang, Haiyu Pang, Lingjuan Jiang, Bintao Qiu, Xiuting Chen, et al. Alterations in the gut microbiome and metabolism with coronary artery disease severity. *Microbiome*, 7:1–14, 2019.

[2] Takumi Toya, Michel T Corban, Eric Marrietta, Irina E Horwath, Lilach O Lerman, Joseph A Murray, and Amir Lerman. Coronary artery disease is associated with an altered gut microbiome composition. *PloS one*, 15(1):e0227147, 2020.

[3] Estefania Sanchez-Rodriguez, Alejandro Egea-Zorrilla, Julio Plaza-Díaz, Jerónimo Aragón-Vela, Sergio Muñoz-Quezada, Luis Tercedor-Sánchez, and Francisco Abadia-Molina. The gut microbiota and its implication in the development of atherosclerosis and related cardiovascular diseases. *Nutrients*, 12(3):605, 2020.

[4] Marko Novakovic, Amit Rout, Thomas Kingsley, Robert Kirchoff, Amteshwar Singh, Vipin Verma, Ravi Kant, and Rahul Chaudhary. Role of gut microbiota in cardiovascular diseases. *World journal of cardiology*, 12(4):110, 2020.

[5] Francesco Violi, Vittoria Cammisotto, Simona Bartimoccia, Pasquale Pignatelli, Roberto Carnevale, and Cristina Nocella. Gut-derived low-grade endotoxaemia, atherothrombosis and cardiovascular disease. *Nature reviews cardiology*, 20(1):24–37, 2023.

[6] Anna Oniszczuk, Tomasz Oniszczuk, Marek Gancarz, and Jolanta Szymańska. Role of gut microbiota, probiotics and prebiotics in the cardiovascular diseases. *Molecules*, 26(4):1172, 2021.

[7] J Mark Brown and Stanley L Hazen. Microbial modulation of cardiovascular disease. *Nature Reviews Microbiology*, 16(3):171–181, 2018.

[8] Ana M Valdes, Jens Walter, Eran Segal, and Tim D Spector. Role of the gut microbiota in nutrition and health. *Bmj*, 361, 2018.

[9] Francois Brial, Aurélie Le Lay, Marc-Emmanuel Dumas, and Dominique Gauguier. Implication of gut microbiota metabolites in cardiovascular and metabolic diseases. *Cellular and molecular life sciences*, 75:3977–3990, 2018.

[10] Negin Kazemian, Morteza Mahmoudi, Frank Halperin, Joseph C Wu, and Sepideh Pakpour. Gut microbiota and cardiovascular disease: opportunities and challenges. *Microbiome*, 8:1–17, 2020.

[11] Viktoria Dotz and Manfred Wuhrer. Histo-blood group glycans in the context of personalized medicine, 2019.

[12] Samitha Somathilaka, Daniel P. Martins, Wiley Barton, Orla O'Sullivan, Paul D. Cotter, and Sasitharan Balasubramaniam. A graph-based molecular communications model analysis of the human gut bacteriome, 2021.

[13] Xiaokang Jia, Wen Xu, Lei Zhang, Xiaoyan Li, Ruirui Wang, and Shuisheng Wu. Impact of gut microbiota and microbiota-related metabolites on hyperlipidemia. *Frontiers in Cellular and Infection Microbiology*, 11:634780, 2021.

[14] Federica Di Vincenzo, Angelo Del Gaudio, Valentina Petito, Loris Riccardo Lopetuso, and Franco Scaldaferri. Gut microbiota, intestinal permeability, and systemic inflammation: a narrative review. *Internal and emergency medicine*, 19(2):275–293, 2024.

[15] Denise Mafra, Natália Borges, Livia Alvarenga, Marta Esgalhado, Ludmila Cardozo, Bengt Lindholm, and Peter Stenvinkel. Dietary components that may influence the disturbed gut microbiota in chronic kidney disease. *Nutrients*, 11(3):496, 2019.

[16] Rasnik K Singh, Hsin-Wen Chang, DI Yan, Kristina M Lee, Derya Ucmak, Kirsten Wong, Michael Abrouk, Benjamin Farahnik, Mio Nakamura, Tian Hao Zhu, et al. Influence of diet on the gut microbiome and implications for human health. *Journal of translational medicine*, 15:1–17, 2017.

[17] Gibong Hong, Veronica Hindle, Nadine M. Veasley, Hannah D. Holscher, and Halil Kilicoglu. Dimb-re: Mining the scientific literature for diet-microbiome associations, 2024.

[18] WH Wilson Tang, Daniel Y Li, and Stanley L Hazen. Dietary metabolism, the gut microbiome, and heart failure. *Nature Reviews Cardiology*, 16(3):137–154, 2019.

[19] Hyo Suk Nam. Gut microbiota and ischemic stroke: the role of trimethylamine n-oxide. *Journal of stroke*, 21(2):151, 2019.

[20] Shengjie Yang, Xinye Li, Fan Yang, Ran Zhao, Xiandu Pan, Jiaqi Liang, Li Tian, Xiaoya Li, Longtao Liu, Yanwei Xing, et al. Gut microbiota-dependent marker tmao in promoting cardiovascular disease: inflammation mechanism, clinical prognostic, and potential as a therapeutic target. *Frontiers in pharmacology*, 10:1360, 2019.

[21] Xinyi Shen, Lihua Li, Zhen Sun, Guangyao Zang, Lili Zhang, Chen Shao, and Zhongqun Wang. Gut microbiota and atherosclerosis—focusing on the plaque stability. *Frontiers in Cardiovascular Medicine*, 8:668532, 2021.

[22] Xin Zhou, Jing Li, Junli Guo, Bin Geng, Wenjie Ji, Qian Zhao, Jinlong Li, Xinlin Liu, Junxiang Liu, Zhaozeng Guo, et al. Gut-dependent microbial translocation induces inflammation and cardiovascular events after st-elevation myocardial infarction. *Microbiome*, 6:1–17, 2018.

[23] Review.

AI-generated, for reference only.

Disclaimer:

SurveyX is an AI-powered system designed to automate the generation of surveys. While it aims to produce high-quality, coherent, and comprehensive surveys with accurate citations, the final output is derived from the AI's synthesis of pre-processed materials, which may contain limitations or inaccuracies. As such, the generated content should not be used for academic publication or formal submissions and must be independently reviewed and verified. The developers of SurveyX do not assume responsibility for any errors or consequences arising from the use of the generated surveys.

AI-generated, for reference only.